

Research article

MiR-608 rs4919510 C>G polymorphism increased the risk of bladder cancer in an Iranian population

Mohammad Hashemi^{1,2,*}, Fatemeh Bizhani², Hiva Danesh², Behzad Narouie^{1,3}, Mehdi Sotoudeh³, Mohammad Hadi Radfar³, Mehdi Honarkar Ramezani³, Gholamreza Bahari², Mohsen Taheri⁴ and Saeid Ghavami⁵

¹ Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

² Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

³ Urology and Nephrology Research Center; Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴ Genetic of non-communicable disease research Center, Zahedan University of Medical Sciences, Zahedan, Iran

⁵ Department of Human Anatomy and Cell Science, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

* **Correspondence:** Email: hashemim@zaums.ac.ir; Tel: +9854 33295722.

Abstract: MicroRNAs (miRNAs) participate in diverse biological pathways and may act as oncogenes or tumor suppressors. The single nucleotide polymorphisms (SNPs) in miRNAs potentially can alter miRNA-binding sites on target genes as well as affecting miRNAs expression. The present study aimed to evaluate the impact of miR-608 rs4919510 C>G variant on bladder cancer risk. This case-control study conducted on 233 bladder cancer patients and 252 healthy subjects. Genotyping of miR-608 rs4919510 was done using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Our findings showed that CG as well as CG+GG genotypes significantly increased the risk of bladder cancer (OR = 1.94, 95% CI = 1.28–2.94, $p = 0.002$, and OR = 1.90, 95% CI = 1.26–2.86, $p = 0.002$, respectively) compared to CC genotype. The G allele significantly increased the risk of bladder cancer compared to C allele (OR = 1.69, 95% CI = 1.17–2.45, $p = 0.005$). Our findings proposed that miR-608 polymorphism might be associated with increased risk of bladder cancer in a sample of Iranian population. Further large-scale studies with different ethnicities are needed to verify our findings.

Keywords: miR-608; bladder cancer; polymorphism

1. Introduction

Bladder cancer (BC) is one of the most frequently-diagnosed malignancies worldwide, with an estimated 430,000 new cases diagnosed in 2012 [1,2]. In the United States, there are about 69,000 newly diagnosed and approximately 15,000 deaths occurred of BC in 2014 [3]. It has been proposed that in addition to the environmental factors such as smoking, obesity, and physical inactivity [4-6], genetic factors can also play an important role in the BC development [7-10].

MicroRNAs (miRNAs) are a highly conserved single-stranded non-coding RNAs of ~22 nucleotides that regulate posttranscriptional gene expression by binding to the 3'-UTR of their target messenger RNAs (mRNAs) and inducing either translational repression or mRNA degradation [11,12]. Single nucleotide polymorphisms (SNPs) in miRNA genes, including primary miRNAs (pri-miRNAs), precursor miRNAs (pre-miRNAs), and mature miRNAs can affect biogenesis, processing, and target binding affinity and specificity [13,14].

The mir-608 gene is located on chromosome 10 (10q24.31) within an intron of the SEMA4G gene. It has been suggested that rs4919510 variant of mir-608 affecting the mature miR-608 sequence [15]. The predicted targets of miR-608 comprise insulin receptor (INSR), interleukin-1 alpha (IL1A), growth hormone receptor (GHR), and TP53 [15].

Several studies inspected the impact of miR-608 rs4919510 C>G polymorphism on the risk as well as outcome in different types of cancer, but the findings were inconsistent [16-27]. To the best of our knowledge, there is no report regarding the impact of miR-608 rs4919510 polymorphism on BC risk. Therefore, this case-control study was designed to assess the possible association between miR-608 rs4919510 polymorphism and susceptibility to BC in an Iranian population.

2. Materials and Methods

2.1. Patients

This case-control study was done on 233 histologically confirmed bladder cancer patients and 252 sex and age matched healthy subjects with no history of cancer of any type (as the control group). All the subjects were enrolled from the Shahid Labbafinejad Medical Center at the Shahid Beheshti University of Medical Sciences, Tehran, Iran. Ethical approvals for recruitment were taken from local Ethics Committee of Zahedan University of Medical Sciences, and informed consent was obtained from all patients and healthy individuals.

2.2. Genotyping

Genotyping of miR-608 rs4919510 C>G was done by PCR-RFLP methods as described previously [28]. The forward and reverse primers were 5'-TCTGGCTAGGTAATGGCTCC-3' and 5'-GCATCTGTGGCCTTCCATGA-3', respectively. Into 0.20 mL reaction solution, 1 µL genomic DNA (~100 ng/mL), 1 µL (10 µM) forward and reverse primers, 10 µL 2X Prime Taq Premix (Genet Bio, Korea), and 7 µL ddH₂O were added. The PCR conditions were as follows: 5 min preheating at

95 °C, 30 cycles of 95 °C for 30 s, 65 °C for 30 s, and 72 °C for 30 s followed by a final extension step for 10 min at 72 °C. Then, 10 µL of PCR product was digested by PvuII restriction enzyme (Fermentas) according to the manufacturer's procedure. The G allele digested and produced two fragments (242-bp and 117-bp), while the C allele undigested (359-bp fragment) (Figure 1).




Figure 1. Photograph of miR608 rs4919510 C>G variant using PCR-RFLP method. The G allele digested by PvuII restriction enzyme and produced 242-bp and 117-bp pattern, while the C allele was undigested (359-bp fragment). M: DNA marker; Lanes 1 and 4: CC; Lane 2: GG; Lane 3: CG.

2.3. Statistical analysis

Statistical analysis was done using statistical package SPSS 22 software. The categorical and continuous data were analyzed using χ^2 and t-test, respectively. The association between genotypes and BC were assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. A p -value of <0.05 was considered to be statistically significant.

3. Results

The study group consisted of 233 bladder cancer patients (193 male, 40 female; age 63.4 ± 12.1 years) and 252 hospital-based healthy subjects (210 male, 42 female; age 62.3 ± 10.7 years). No significant difference was observed between the groups regarding sex and age ($p = 0.904$ and $p = 0.316$, respectively).

The genotype and allele frequencies of miR-608 rs4919510 C>G polymorphism in bladder cancer patients and healthy subjects are shown in Table 1. Our findings showed that rs4919510 CG genotype as well as CG + GG genotype significantly increased the risk of bladder cancer (OR = 1.94, 95% CI = 1.28–2.94, $p = 0.002$ and OR = 1.90, 95% CI = 1.26–2.86, $p = 0.002$, respectively) compared to CC genotype. The G allele was significantly associated with increased the risk of bladder cancer (OR = 1.69, 95% CI = 1.17–2.45, $p = 0.005$) compared to C allele.

Table 1. Association of miR-608 rs4919510 C>G polymorphism and risk of bladder cancer.

miR608 rs4919510 C>G	Case n (%)	Control n (%)	OR (95%CI)	<i>p</i>
Genotype				
CC	156 (67.0)	200 (79.4)	1.00	-
CG	74 (31.7)	49 (19.4)	1.94 (1.28–2.94)	0.002
GG	3 (1.3)	3 (1.2)	1.28 (0.26–6.44)	0.986
CG+GG	77 (33.0)	52 (20.6)	1.90 (1.26–2.86)	0.002
Allele				
C	386 (82.8)	449 (89.1)	1.00	-
G	80 (17.2)	55 (10.9)	1.69 (1.17–2.45)	0.005

Hardy-Weinberg equilibrium (HWE) was assessed by χ^2 test. The genotype of miR-608 rs4919510 polymorphism in both controls and cases were in HWE ($\chi^2 = 4.13$, $p = 0.999$ and $\chi^2 = 3.17$, $p = 0.074$, respectively).

No significant association between miR-608 rs4919510 genotypes and clinicopathological characteristics (age, sex, histologic type, stage) of BC patients was found (data not showed).

4. Conclusion

For the first time, we examined the impact of miR-608 rs4919510 variant on the risk of BC in a sample of Iranian population. The findings indicated that CG, CG + GG genotypes as well as G allele significantly increased the risk of BC in our population. We found no significant association between miR-608 rs4919510 genotypes and clinicopathological characteristics (age, sex, histologic type, stage of BC patients (data not showed).

Several studies inspected the association between mir-608 rs4919510 variant and development of various cancer, but the results are inconsistent. Qiu et al. [29] have found that miR-608 rs4919510 polymorphism is associated with an increased risk of nasopharyngeal carcinoma in southern China (GC + GG vs CC genotype, OR = 1.36, 95% CI = 1.10–1.70) and eastern China (GC + GG vs CC, OR = 1.37, 95% CI = 1.08–1.74). After they merged the two populations the ORs and 95%CI were 1.38 and 1.18 to 1.62, respectively.

No significant association were found between rs4919510 variant and risk of thyroid cancer [16], colorectal cancer [18,20], hepatocellular carcinoma [21], esophageal squamous cell carcinoma (ESCC) [22], breast cancer [23,30,31], lung cancer [32,33], and gastric cancer [34]. We have shown previously that mir-608 rs4919510 variant significantly decreased the risk of breast cancer [28]. Jiao et al. [17] have found no significant association between miR-608 rs4919510 polymorphism and breast cancer survival in Chinese population. Huang et al. [30] have observed that miR-608 rs4919510 variant is associated with increased risk of HER2-positive breast cancer. It has been proposed that mir-608 rs4919510 polymorphism may be a potential marker of hepatocellular carcinoma (HCC) [24,35], and colorectal cancer (CRC) [20,36,37]. A meta-analysis performed by Liu et al. [38] revealed that miR-608 rs4919510 variant significantly decreased cancer risk in recessive model (OR = 0.89, 95% CI = 0.82–0.97, $p = 0.009$, CC vs GG + GC).

Aberrant expression of miR-608 has been reported in cases of esophageal squamous cell carcinoma [27], breast cancer [30], colorectal cancer [36,37], ovarian cancer [39], lung cancer [35,40], and cancer lines of chordoma [41]. Dysregulation expression of miR-608 could affect the risk of cancer by altering the expression of mRNA targets.

It cannot currently clarify the precise functional mechanism through which miR-608 rs4919510 affect bladder cancer risk. Although the variant does not lie within the seed sequence of miR-608, it lies within the mature sequence of miR-608 and is located at the junction between the stem and canonical hairpin loop [20]. As this rigid secondary structure is a required for recognition and processing of pre-miRNA, it is possible that disruption of structure at this critical point might affect recognition or subsequent processing. Since each miRNA has many different targets, deregulation of miRNA expression has been associated with many pathological conditions, including various cancers [15,42,43].

In summary, this study provides the first evidence that miR-608 rs4919510 variant increased the risk of bladder cancer in a sample of Iranian population. However, we found no significant association between this variant and the clinicopathological characteristics of BC patients. Further studies with larger sample sizes with different ethnicities are essential to confirm our finding.

Acknowledgement

This paper was funded by a research grant from the Deputy for Research, Zahedan University of Medical Sciences.

Conflict of interests

The Authors declare that there is no conflict of interest to disclose.

References

1. Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108.
2. Antoni S, Ferlay J, Soerjomataram I, et al. (2016) Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *Eur Urol*.
3. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* 507: 315-322.
4. Shiels MS, Gibson T, Sampson J, et al. (2014) Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. *J Clin Oncol* 32: 3989-3995.
5. Vermeulen SH, Hanum N, Grotenhuis AJ, et al. (2015) Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. *Br J Cancer* 112: 594-600.
6. Burger M, Catto JW, Dalbagni G, et al. (2013) Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol* 63: 234-241.
7. Giedl J, Rogler A, Wild A, et al. (2016) TERT Core Promotor Mutations in Early-Onset Bladder Cancer. *J Cancer* 7: 915-920.
8. Sankhwar M, Sankhwar SN, Bansal SK, et al. (2016) Polymorphisms in the XPC gene affect

- urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. *Sci Rep* 6: 27018.
9. Hua Q, Lv X, Gu X, et al. (2016) Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population. *Mutagenesis*: gew018
 10. Aben KK, Witjes JA, Schoenberg MP, et al. (2002) Familial aggregation of urothelial cell carcinoma. *Int J Cancer* 98: 274-278.
 11. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5: 522-531.
 12. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297.
 13. Lee Y, Kim M, Han J, et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. *EMBO J* 23: 4051-4060.
 14. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. *Nat Rev Cancer* 10: 389-402.
 15. Landi D, Gemignani F, Barale R, et al. (2008) A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. *DNA Cell Biol* 27: 35-43.
 16. Wei WJ, Wang YL, Li DS, et al. (2015) Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population. *Endocrine* 49: 436-444.
 17. Jiao L, Zhang J, Dong Y, et al. (2014) Association between miR-125a rs12976445 and survival in breast cancer patients. *Am J Transl Res* 6: 869-875.
 18. Kupcinskis J, Bruzaite I, Juzenas S, et al. (2014) Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. *Sci Rep* 4: 5993.
 19. Lin M, Gu J, Eng C, et al. (2012) Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. *Clin Cancer Res* 18: 3982-3991.
 20. Ryan BM, McClary AC, Valeri N, et al. (2012) rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. *PLoS One* 7: e36306.
 21. Wang R, Zhang J, Ma Y, et al. (2014) Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a largescale population. *Mol Med Rep* 10: 2736-2744.
 22. Zhang P, Wang J, Lu T, et al. (2015) miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. *Tumour Biol* 36: 8789-8795.
 23. Morales S, Gulppi F, Gonzalez-Hormazabal P, et al. (2016) Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. *BMC Genet* 17: 109.
 24. Ma XP, Yu G, Chen X, et al. (2016) MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. *Tumour Biol* 2016: 1-12.
 25. Sciafani F, Chau I, Cunningham D, et al. (2016) Sequence Variation in Mature MicroRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. *Carcinogenesis*: bgw073.
 26. Jiang J, Jia ZF, Cao DH, et al. (2016) Association of the miR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis. *Future Oncol* 0.
 27. Yang PW, Huang YC, Hsieh CY, et al. (2014) Association of miRNA-related Genetic Polymorphisms and Prognosis in Patients with Esophageal Squamous Cell Carcinoma. *Ann Surg Oncol* 21: 601-609.

28. Hashemi M, Sanaei S, Rezaei M, et al. (2016) miR-608 rs4919510 C>G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. *Exp Oncol* 38: 57-59.
29. Qiu F, Yang L, Zhang L, et al. (2015) Polymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma. *Gene* 565: 180-186.
30. Huang AJ, Yu KD, Li J, et al. (2012) Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. *PLoS One* 7: e35252.
31. Dai ZM, Kang HF, Zhang WG, et al. (2016) The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study. *Medicine (Baltimore)* 95: e2826.
32. Yin Z, Cui Z, Guan P, et al. (2015) Interaction between Polymorphisms in Pre-MiRNA Genes and Cooking Oil Fume Exposure on the Risk of Lung Cancer in Chinese Non-Smoking Female Population. *PLoS One* 10: e0128572.
33. Yin Z, Cui Z, Ren Y, et al. (2016) Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population. *Lung Cancer* 94: 15-21.
34. Kupcinskis J, Wex T, Link A, et al. (2014) Gene polymorphisms of micrnas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. *PLoS One* 9: e87467.
35. Wang K, Liang Q, Wei L, et al. (2016) MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor. *Tumour Biol* 37: 3823-3830.
36. Xing J, Wan S, Zhou F, et al. (2012) Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 21: 217-227.
37. Pardini B, Rosa F, Naccarati A, et al. (2015) Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. *Carcinogenesis* 36: 82-86.
38. Liu H, Zhou Y, Liu Q, et al. (2016) Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects. *Oncotarget*.
39. Rah H, Kim HS, Cha SH, et al. (2015) Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency. *Menopause* 22: 437-443.
40. Li D, Zhu G, Di H, et al. (2016) Associations between genetic variants located in mature microRNAs and risk of lung cancer. *Oncotarget*.
41. Zhang Y, Schiff D, Park D, et al. (2014) MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. *PLoS One* 9: e91546.
42. Hezaveh K, Kloetgen A, Bernhart SH, et al. (2016) Alterations of miRNAs and miRNA-regulated mRNA expression in GC B cell lymphomas determined by integrative sequencing analysis. *Haematologica*.
43. Marzec-Kotarska B, Cybulski M, Kotarski JC, et al. (2016) Molecular bases of aberrant miR-182 expression in ovarian cancer. *Genes Chromosomes Cancer* 55: 877-889.



AIMS Press

© 2016 Mohammad Hashemi et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)